Lawyers from the law firms that make up the BIOLAWEurope FmbA organization, as part of the celebration of the 10th anniversary of the establishment of the organization of firms specializing in the regulatory pharmaceutical law and life science market, took part in a visit to the Danish Parliament building. The meeting was led by Jan Ejnar Jørgensen, MEP, Attorney-at-Law, elected for and member of “Venstre”, The Liberal Party of Denmark (Member of the Alliance of Liberals and Democrats for Europe (ALDE)), who, as a practicing Danish lawyer and currently, the parliamentarian has devoted his valuable time to showing BIOLAW EUROPE lawyers around the key places of the Parliament in Copenhagen, including the historic and current Plenary Hall, and working rooms, including special conference rooms referring, among others, to the Greenlandic tradition.
The visit to the Danish Parliament was one of many key exclusive events accompanying the general meeting of the BIOLAW EUROPE association. The event was organized by Jan Bierrum Bach, Danish lawyer, Jusmedico, founder of BIOLAWEUROPE FmbA.
Decision-making methods in collective bodies of limited liability companies and joint-stock companies.
Limited liability company
The shareholders’ meeting, the audit committee, the management board and the supervisory board are the collective bodies of a limited liability company. The Polish Commercial Companies Code introduces many regulations that allow the use of means of direct distance communication in order to improve the voting process in capital companies. Means of electronic communication are technical solutions, including ICT devices and software tools cooperating with them, enabling individual communication at a distance using data transmission between ICT systems.
Artificial intelligence (AI) is a field of science that deals with the creation and use of computer systems that can simulate human cognitive processes, such as learning, reasoning, decision-making and problem solving. AI has an increasing impact on various aspects of our lives, including medicine and health. This article will discuss how AI changes clinical trials, i.e. the process of testing new drugs and therapies on humans before they are approved for marketing and use.
